Table 1.

Summary of design and characteristics of studies included in the meta-analysis.

Study	Design	Location	Hospitalization	Exposure	Mortality
Arshad 2020	Observational Cohort	USA	Hospitalized	HCQ (n = 1202) vs. HCQ + AZI (n = 783) vs. AZI (n = 147) vs. Control (n = 409)	162/1202 vs. 157/783 vs. 33/147 vs. 108/409
Cavalcanti 2020	RCT	Brazil	Hospitalized	HCQ (n = 159) vs. HCQ + AZI (n = 172) vs. Control (n = 173)	5/159 vs. 3/172 vs. 5/173
Di Castelnuovo 2020	Observational Cohort	Italy	Hospitalized	HCQ (n = 2634) vs. Control (n = 817)	386/2634 vs. 190/817
Geleris 2020	Observational Cohort	USA	Hospitalized	HCQ ± AZI (n = 811) vs. No HCQ ± AZI (n = 565)	157/811 vs. 75/565
Horby 2020	RCT	UK	Hospitalized	HCQ (n = 1561) vs. Control (n = 3155)	421/1561 vs. 790/3155
Ip 2020	Observational Cohort	USA	Hospitalized	HCQ ± AZI (n = 1914) vs. Control ± AZI (n = 598)	432/1914 vs. 115/598
Magagnoli 2020	Observational Cohort	USA	Hospitalized	HCQ (n = 97) vs. HCQ + AZI (n = 113) vs. Control (n = 158)	27/97 vs. 25/113 vs. 18/158
Mahevas 2020	Observational Cohort	France	Hospitalized	HCQ (n = 84) vs. Control (n = 97)	3/84 vs. 4/97
Membrillo 2020	Observational Cohort	Spain	Hospitalized	HCQ (n = 123) vs. Control (n = 43)	27/123 vs. 21/43
Paccoud 2020	Observational Cohort	France	Hospitalized	HCQ (n = 38) vs. Control (n = 46)	3/38 vs. 6/46
Rosenberg 2020	Observational Cohort	USA	Hospitalized	HCQ (n = 271) vs. HCQ + AZI (n = 735) vs. AZI (n = 211) vs. Control (n = 221)	54/271 vs. 189/735 vs. 21/211 vs. 28/221
Sibidian 2020	Observational Cohort	France	Hospitalized	HCQ (n = 623) vs. HCQ + AZI (n = 227) vs. Control (3792)	126/623 vs. 56/227 vs. 865/3792
Singh 2020	Observational Cohort	USA	Hospitalized	HCQ (n = 1125) vs. Control (n = 2247)	104/910 vs. 109/910
Yu 2020	Observational Cohort	China	Hospitalized	HCQ (n = 48) vs. Control (n = 520)	9/48 vs. 238/520

AZI: Azithromycin, HCQ: Hydroxychloroquine, RCT: Randomized Clinical Trial.